User contributions for Parth Vikram Singh
Results for Parth Vikram Singh talk block log uploads logs
A user with 21 edits. Account created on 28 January 2025.
14 February 2025
- 01:0901:09, 14 February 2025 diff hist +3,246 Inavolisib No edit summary current Tag: Visual edit
- 00:4300:43, 14 February 2025 diff hist +5,354 Inavolisib No edit summary
13 February 2025
- 20:3720:37, 13 February 2025 diff hist +21 Inavolisib No edit summary
- 20:3620:36, 13 February 2025 diff hist +1,164 Inavolisib No edit summary
- 20:2720:27, 13 February 2025 diff hist +1 Inavolisib No edit summary
- 20:2520:25, 13 February 2025 diff hist +1,494 Inavolisib No edit summary
- 20:1120:11, 13 February 2025 diff hist −16 Inavolisib No edit summary
- 20:0720:07, 13 February 2025 diff hist +12 Inavolisib No edit summary
- 20:0620:06, 13 February 2025 diff hist +1,300 Inavolisib No edit summary
- 20:0120:01, 13 February 2025 diff hist +14 Inavolisib No edit summary
- 20:0020:00, 13 February 2025 diff hist +1 Inavolisib No edit summary
- 19:5919:59, 13 February 2025 diff hist +1,537 Inavolisib No edit summary
- 19:3319:33, 13 February 2025 diff hist +485 Inavolisib No edit summary
- 18:3418:34, 13 February 2025 diff hist +2,725 Inavolisib No edit summary
- 18:1718:17, 13 February 2025 diff hist +6 Inavolisib No edit summary Tag: Manual revert
- 18:1618:16, 13 February 2025 diff hist −6 Inavolisib No edit summary
- 18:1418:14, 13 February 2025 diff hist +4,239 Inavolisib No edit summary
- 17:3517:35, 13 February 2025 diff hist +2 Inavolisib No edit summary
- 17:3417:34, 13 February 2025 diff hist +295 Inavolisib No edit summary
- 14:5514:55, 13 February 2025 diff hist +191 Inavolisib No edit summary
- 02:4702:47, 13 February 2025 diff hist +1,951 N Inavolisib Created page with "{{DrugProjectFormSinglePage |authorTag=Parth Vikram Singh |genericName=Inavolisib |aOrAn=a |drugClass=phosphoinositide 3-kinase inhibitors |indicationType=treatment |indication=Inavolisib is a phosphoinositide 3-kinase inhibitor that is FDA approved for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer Breast cancer,..."